{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:04:41Z","timestamp":1746417881320,"version":"3.40.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.7759\/cureus.83470","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T20:22:18Z","timestamp":1746390138000},"source":"Crossref","is-referenced-by-count":0,"title":["Transient Acquired von Willebrand Disease With a Type 2B Phenotype: Recognizing the Diagnostic Challenges"],"prefix":"10.7759","author":[{"given":"Sumayya","family":"Aslam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lila","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rabichow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse C","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell NT","year":"2021","unstructured":"Connell NT, Flood VH, Brignardello-Petersen R, et al.. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021, 5:301-25. 10.1182\/bloodadvances.2020003264","journal-title":"Blood Adv"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4065\/77.2.181","article-title":"Acquired von Willebrand disease","volume":"77","author":"Kumar S","year":"2002","unstructured":"Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc. 2002, 77:181-7. 10.4065\/77.2.181","journal-title":"Mayo Clin Proc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5551\/jat.RV17031","article-title":"Acquired von Willebrand syndrome associated with cardiovascular diseases","volume":"26","author":"Horiuchi H","year":"2019","unstructured":"Horiuchi H, Doman T, Kokame K, Saiki Y, Matsumoto M. Acquired von Willebrand syndrome associated with cardiovascular diseases. J Atheroscler Thromb. 2019, 26:303-14. 10.5551\/jat.RV17031","journal-title":"J Atheroscler Thromb"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e328342486a","article-title":"Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome","volume":"22","author":"Karger R","year":"2011","unstructured":"Karger R, Weippert-Kretschmer M, Budde U, Kretschmer V. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome. Blood Coagul Fibrinolysis. 2011, 22:144-7. 10.1097\/MBC.0b013e328342486a","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000353525","article-title":"Acquired von Willebrand syndrome with a type 2B phenotype: diagnostic and therapeutic dilemmas","volume":"131","author":"Scepansky E","year":"2014","unstructured":"Scepansky E, Othman M, Smith H. Acquired von Willebrand syndrome with a type 2B phenotype: diagnostic and therapeutic dilemmas. Acta Haematol. 2014, 131:213-7. 10.1159\/000353525","journal-title":"Acta Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102516","article-title":"A rare case of acquired von Willebrand syndrome type 2B: diagnosis, treatment, and underlying pathophysiology","volume":"8","author":"Jaouen S","year":"2024","unstructured":"Jaouen S, Mingant F, Pan-Petesch B, Lippert E, Jeanpierre E, Galinat H. A rare case of acquired von Willebrand syndrome type 2B: diagnosis, treatment, and underlying pathophysiology. Res Pract Thromb Haemost. 2024, 8:102516. 10.1016\/j.rpth.2024.102516","journal-title":"Res Pract Thromb Haemost"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2001.0141","article-title":"Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management","volume":"14","author":"Michiels JJ","year":"2001","unstructured":"Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol. 2001, 14:401-36. 10.1053\/beha.2001.0141","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/850810","article-title":"Conventional rapid latex agglutination in estimation of von Willebrand factor: method revisited and potential clinical applications","volume":"2014","author":"Mahat M","year":"2014","unstructured":"Mahat M, Abdullah WZ, Hussin CM. Conventional rapid latex agglutination in estimation of von Willebrand factor: method revisited and potential clinical applications. J Immunol Res. 2014, 2014:850810. 10.1155\/2014\/850810","journal-title":"J Immunol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00260.x","article-title":"Von Willebrand factor, platelets and endothelial cell interactions","volume":"1","author":"Ruggeri ZM","year":"2003","unstructured":"Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost. 2003, 1:1335-42. 10.1046\/j.1538-7836.2003.00260.x","journal-title":"J Thromb Haemost"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.11.016","article-title":"Rise of levels of von Willebrand factor and factor VIII with age: role of genetic and acquired risk factors","volume":"197","author":"Biguzzi E","year":"2021","unstructured":"Biguzzi E, Castelli F, Lijfering WM, Cannegieter SC, Eikenboom J, Rosendaal FR, van Hylckama Vlieg A. Rise of levels of von Willebrand factor and factor VIII with age: role of genetic and acquired risk factors. Thromb Res. 2021, 197:172-8. 10.1016\/j.thromres.2020.11.016","journal-title":"Thromb Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2892","article-title":"von Willebrand disease type 1: a diagnosis in search of a disease","volume":"101","author":"Sadler JE","year":"2003","unstructured":"Sadler JE. von Willebrand disease type 1: a diagnosis in search of a disease. Blood. 2003, 101:2089-93. 10.1182\/blood-2002-09-2892","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13696","article-title":"von Willebrand factor and inflammation","volume":"15","author":"Kawecki C","year":"2017","unstructured":"Kawecki C, Lenting PJ, Denis CV. von Willebrand factor and inflammation. J Thromb Haemost. 2017, 15:1285-94. 10.1111\/jth.13696","journal-title":"J Thromb Haemost"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179566","article-title":"Type 2B von Willebrand disease with or without large multimers: a distinction of the two sides of the disorder is long overdue","volume":"12","author":"Casonato A","year":"2017","unstructured":"Casonato A, Daidone V, Galletta E, Bertomoro A. Type 2B von Willebrand disease with or without large multimers: a distinction of the two sides of the disorder is long overdue. PLoS One. 2017, 12:e0179566. 10.1371\/journal.pone.0179566","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.019927","article-title":"Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia","volume":"95","author":"Casonato A","year":"2010","unstructured":"Casonato A, Gallinaro L, Cattini MG, et al.. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. Haematologica. 2010, 95:1366-72. 10.3324\/haematol.2009.019927","journal-title":"Haematologica"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1660481","article-title":"Evaluation of the utility of von Willebrand factor propeptide in the differential diagnosis of von Willebrand disease and acquired von Willebrand syndrome","volume":"45","author":"Stufano F","year":"2019","unstructured":"Stufano F, Boscarino M, Bucciarelli P, Baronciani L, Maino A, Cozzi G, Peyvandi F. Evaluation of the utility of von Willebrand factor propeptide in the differential diagnosis of von Willebrand disease and acquired von Willebrand syndrome. Semin Thromb Hemost. 2019, 45:36-42. 10.1055\/s-0038-1660481","journal-title":"Semin Thromb Hemost"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2014.1.524","article-title":"Clinical and laboratory diagnosis of VWD","volume":"2014","author":"Federici AB","year":"2014","unstructured":"Federici AB. Clinical and laboratory diagnosis of VWD. Hematology Am Soc Hematol Educ Program. 2014, 2014:524-30. 10.1182\/asheducation-2014.1.524","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14971","article-title":"Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers","volume":"18","author":"Szederjesi A","year":"2020","unstructured":"Szederjesi A, Baronciani L, Budde U, et al.. Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers. J Thromb Haemost. 2020, 18:2513-23. 10.1111\/jth.14971","journal-title":"J Thromb Haemost"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00536-8","article-title":"von Willebrand disease","volume":"10","author":"Seidizadeh O","year":"2024","unstructured":"Seidizadeh O, Eikenboom JC, Denis CV, et al.. von Willebrand disease. Nat Rev Dis Primers. 2024, 10:51. 10.1038\/s41572-024-00536-8","journal-title":"Nat Rev Dis Primers"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2020.1832017","article-title":"Rituximab-induced acute thrombocytopenia in patients with splenomegaly B Cell lymphoma: an underdiagnosed but severe complication","volume":"21","author":"Jiang Y","year":"2020","unstructured":"Jiang Y, Song J, Wang N, Yuan D, Feng L, Qu H, Fan J. Rituximab-induced acute thrombocytopenia in patients with splenomegaly B Cell lymphoma: an underdiagnosed but severe complication. Cancer Biol Ther. 2020, 21:1060-6. 10.1080\/15384047.2020.1832017","journal-title":"Cancer Biol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07538.x","article-title":"Is rituximab effective in acquired von Willebrand syndrome?","volume":"144","author":"Mazoyer E","year":"2009","unstructured":"Mazoyer E, Fain O, Dhote R, Laurian Y. Is rituximab effective in acquired von Willebrand syndrome?. Br J Haematol. 2009, 144:967-8. 10.1111\/j.1365-2141.2008.07538.x","journal-title":"Br J Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/363320-transient-acquired-von-willebrand-disease-with-a-type-2b-phenotype-recognizing-the-diagnostic-challenges","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T20:22:19Z","timestamp":1746390139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/363320-transient-acquired-von-willebrand-disease-with-a-type-2b-phenotype-recognizing-the-diagnostic-challenges"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,4]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.83470","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,4]]}}}